Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience

• Published in: Medical oncology (Northwood, London, England) Vol. 30; no. 1; p. 429
• Main Authors: Yust-Katz, Shlomit, Mathis, Samuel, Groves, Morris D.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-03-2013; Springer Nature B.V
• Subjects: Adult; Aged; Female; Hematology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Meningeal Carcinomatosis - epidemiology; Meningeal Carcinomatosis - secondary; Middle Aged; Oncology; Pathology; Short Communication; Urogenital Neoplasms - pathology; Young Adult; Genitourinary cancer; Leptomeningeal metastases; MD Anderson Cancer Center
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-012-0429-z

Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed. Out of 93960 GU cancer patients treated in MD Anderson (cervix cancer 13,289, ovarian cancer 13,126, bladder cancer 11,834, prostate cancer 41,830, and kidney 13,881), 31 cases (0.03 %) of GU cancer with LM were identified in MD Anderson Cancer Center (MDACC) between 1978 and 2011. Eight patients had bladder cancer, 4 had cervical cancer, 4 had renal cancer, 8 had ovarian cancer and 7 had prostate cancer. Mean age of diagnosis of cancer was 55.9 ± 11.7 (range 20–74). Mean time from primary diagnosis to LM diagnosis was 141.46 ± 244 weeks (range 0.43–409.57). Median survival after LM diagnosis was 15.7 weeks (range 0.85–142.57). The patients presented with multiple signs and symptoms. Although rare—LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits.